← Back

Wire · founder news, decoded · opportunities

Real-world evidence and AI: How EHR data is reshaping drug development decisions

Published

22 July 2026

Topic

opportunities

Sectors

Digital HealthDrug DiscoveryAI Infrastructure

Geography

United StatesEurope

Source

Read at drugdiscoverynews.com

Verified

Fusion42 · 22 July 2026 · Fusion42 review

AI and natural language processing now enable drug developers to mine unstructured EHR data at scale to inform trial design, patient stratification, and safety monitoring. The FDA and EMA have issued frameworks accepting real-world evidence, moving the practice from regulatory aspiration into operational use within sponsor organisations.

This Wire brief sits within Fusion42's coverage of Digital Health, Drug Discovery and AI Infrastructure. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.

The Wire takeaway

If you build tools to help drug companies extract signal from messy clinical notes, you now have regulatory cover to sell directly into sponsor organisations' development workflows. Regulators have moved from 'maybe someday' to 'here's how to do it right', and that opens a procurement cycle.

Related on Wire

Topics

Digital Health · Drug Discovery · AI Infrastructure · real-world-evidence · ai-nlp · clinical-data · drug-development · patient-stratification